Literature DB >> 1856477

Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection.

L J Markoff1, B L Innis, R Houghten, L S Henchal.   

Abstract

The four serotypes of dengue virus (a mosquito-borne flavivirus) cause an acute febrile illness (dengue fever) or a more prolonged illness with plasma leakage resulting in hypovolemia (dengue hemorrhagic fever). Hemorrhage may accompany either. Epidemiologic data suggest a role for dengue antibodies in pathogenesis. Computer analysis revealed a 20-residue region of similarity in amino acid sequence between the dengue type 4 envelope glycoprotein (E) and a family of clotting factors, including plasminogen, the prime mediator of fibrinolysis. By use of synthetic peptides in ELISA, E antibodies that potentially bind plasminogen were detected in 75% of 40 Thai patients acutely infected with dengue virus type 1, 2, 3, or 4. Plasminogen cross-reactivity of dengue antibodies was shown to be specific for the related sites in E and plasminogen. The dengue E sequence with similarity to plasminogen is largely conserved within the currently known flavivirus E sequences. However, 15 Thai patients hospitalized for illness caused by Japanese encephalitis virus (a flavivirus not associated with hemorrhage) did not develop plasminogen-cross-reactive antibodies, and this finding correlated with failure of Japanese encephalitis virus antibodies to bind to the plasminogen-cross-reactive site in E.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856477     DOI: 10.1093/infdis/164.2.294

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

3.  Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections.

Authors:  Sophie Alcon; Antoine Talarmin; Monique Debruyne; Andrew Falconar; Vincent Deubel; Marie Flamand
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 4.  Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology.

Authors:  Lucile Warter; Ramapraba Appanna; Katja Fink
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 5.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

6.  Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis.

Authors:  Yung-Chun Chuang; Yee-Shin Lin; Hsiao-Sheng Liu; Trai-Ming Yeh
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

Review 7.  Dengue virus pathogenesis: an integrated view.

Authors:  Byron E E Martina; Penelope Koraka; Albert D M E Osterhaus
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 8.  Animal models of dengue virus infection.

Authors:  Simona Zompi; Eva Harris
Journal:  Viruses       Date:  2012-01-09       Impact factor: 5.048

Review 9.  Controversies in dengue pathogenesis.

Authors:  Scott B Halstead
Journal:  Paediatr Int Child Health       Date:  2012-05       Impact factor: 1.990

Review 10.  Current progress in dengue vaccines.

Authors:  Shu-Wen Wan; Chiou-Feng Lin; Shuying Wang; Yu-Hung Chen; Trai-Ming Yeh; Hsiao-Sheng Liu; Robert Anderson; Yee-Shin Lin
Journal:  J Biomed Sci       Date:  2013-06-13       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.